Eveliqure Biotechnologies Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

Eveliqure Biotechnologies General Information

Description

Developer of a combined vaccine designed to protect against Shigella as well as against ETEC bacteria. The company's vaccine prevents diarrheal diseases and is based on a live attenuated vaccine strain of the bacterium, engineered to induce broad protection against infection caused by different species and serotypes of this pathogen, helping the healthcare industry to provide vaccines to populations at risk of diarrheal diseases.

Contact Information

Website
www.eveliqure.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Campus Vienna Biocenter
  • Karl-Farkas-Gasse 22
  • Vienna, 1030
  • Austria
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Campus Vienna Biocenter
  • Karl-Farkas-Gasse 22
  • Vienna, 1030
  • Austria

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eveliqure Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 01-Apr-2026 Completed Clinical Trials - Phase 2
6. Angel (individual) 01-Feb-2026 Completed Clinical Trials - Phase 2
5. Later Stage VC 30-Jun-2020 Completed Startup
4. Grant 11-Sep-2019 Completed Startup
3. Later Stage VC 01-Mar-2018 Completed Startup
2. Grant $2.75M Completed Startup
1. Grant $224K Completed Startup
To view Eveliqure Biotechnologies’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Eveliqure Biotechnologies Patents

  • 21

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • 7

    Pending

  • Expiring in next 12 mo

Eveliqure Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021359635-A1 High dose shigella vaccine preparation Pending 14-Oct-2020
AU-2021359635-A9 High dose shigella vaccine preparation Pending 14-Oct-2020
CA-3198656-A1 High dose shigella vaccine preparation Pending 14-Oct-2020
EP-4243861-A1 High dose shigella vaccine preparation Pending 14-Oct-2020
US-12636356-B2 High dose shigella vaccine preparation Active 14-Oct-2020 A61K39/0283
To view Eveliqure Biotechnologies’s complete patent history, request access »

Eveliqure Biotechnologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eveliqure Biotechnologies Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
STRT Holding Angel Group Minority
Baobá Corporation Minority
LifeLink Ventures Venture Capital Minority
Horizon 2020 Government
Österreichische Forschungsförderungsgesellschaft Government
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Eveliqure Biotechnologies FAQs

  • When was Eveliqure Biotechnologies founded?

    Eveliqure Biotechnologies was founded in 2012.

  • Where is Eveliqure Biotechnologies headquartered?

    Eveliqure Biotechnologies is headquartered in Vienna, Austria.

  • What is the size of Eveliqure Biotechnologies?

    Eveliqure Biotechnologies has 6 total employees.

  • What industry is Eveliqure Biotechnologies in?

    Eveliqure Biotechnologies’s primary industry is Drug Discovery.

  • Is Eveliqure Biotechnologies a private or public company?

    Eveliqure Biotechnologies is a Private company.

  • What is Eveliqure Biotechnologies’s current revenue?

    The current revenue for Eveliqure Biotechnologies is .

  • How much funding has Eveliqure Biotechnologies raised over time?

    Eveliqure Biotechnologies has raised $2.47M.

  • Who are Eveliqure Biotechnologies’s investors?

    STRT Holding, Baobá, LifeLink Ventures, Horizon 2020, and Österreichische Forschungsförderungsgesellschaft are 5 of 7 investors who have invested in Eveliqure Biotechnologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process